Replies to post #435 on Armata Pharmaceuticals, Inc. (ARMP)

[Theo]

Today's pop is probably due to this: APHB: Early Signs of Efficacy Seen in Phase 1 Trial of AB-SA01 in Chronic Rhinosinusitis
...
Conclusion

The preliminary results announced for AB-SA01 in the Phase 1 study in patients with CRS are very encouraging, particularly since AB-SA01 was able to safely eradicate S. aureus in two patients that were refractory to antibiotic treatment. We look forward to the full results from the study later in 2016, which we believe is likely to show similar results in Cohort 3 that were seen in Cohort 2.

We have constructed a probability adjusted discounted cash flow model that takes into account the potential market for treating CRS patients with AB-SA01, cystic fibrosis patients with AB-PA01, as well as the amount of capital that will be required to get the first product to market. Our current valuation for AmpliPhi is $11/share, and we continue to remain positive on the AmpliPhi story and believe that bacteriophage therapy has tremendous potential as a treatment for serious and life-threatening bacterial infections.